None
Quote | Arvinas Inc. (NASDAQ:ARVN)
Last: | $31.60 |
---|---|
Change Percent: | 1.66% |
Open: | $32 |
Close: | $31.60 |
High: | $32.13 |
Low: | $30.91 |
Volume: | 636,293 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Arvinas Inc. (NASDAQ:ARVN)
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer....
2024-04-12 08:30:02 ET H.C. Wainwright analyst issues BUY recommendation for ARVN on April 12, 2024 06:52AM ET. The previous analyst recommendation was Buy. ARVN was trading at $37.26 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...
Message Board Posts | Arvinas Inc. (NASDAQ:ARVN)
Subject | By | Source | When |
---|---|---|---|
ARVN up 138% > "Based on data to | crudeoil24 | investorshub | 12/14/2020 2:19:37 PM |
Advantages of PROTACs vs. inhibition... | biocqr | investorshub | 12/17/2019 3:29:22 PM |
Idk about that, I thought it had some | G-lupo | investorshub | 11/29/2019 5:15:41 AM |
Starting to see a chink in the armor! | boo boo | investorshub | 11/26/2019 10:04:01 PM |
Possibly wall at 30.50 | G-lupo | investorshub | 11/15/2019 10:01:32 PM |
News, Short Squeeze, Breakout and More Instantly...
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of...
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer....
2024-04-12 08:30:02 ET H.C. Wainwright analyst issues BUY recommendation for ARVN on April 12, 2024 06:52AM ET. The previous analyst recommendation was Buy. ARVN was trading at $37.26 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...